SciClone Pharmaceuticals (Holdings) (HKSE:06600) 5-Year EBITDA Growth Rate : 20.00% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is SciClone Pharmaceuticals (Holdings) 5-Year EBITDA Growth Rate?

SciClone Pharmaceuticals (Holdings)'s EBITDA per Share for the six months ended in Dec. 2023 was HK$0.93.

During the past 12 months, SciClone Pharmaceuticals (Holdings)'s average EBITDA Per Share Growth Rate was 37.10% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 12.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 20.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of SciClone Pharmaceuticals (Holdings) was 47.90% per year. The lowest was 12.50% per year. And the median was 23.65% per year.

Competitive Comparison of SciClone Pharmaceuticals (Holdings)'s 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, SciClone Pharmaceuticals (Holdings)'s 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SciClone Pharmaceuticals (Holdings)'s 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SciClone Pharmaceuticals (Holdings)'s 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where SciClone Pharmaceuticals (Holdings)'s 5-Year EBITDA Growth Rate falls into.

SciClone Pharmaceuticals (Holdings) 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

SciClone Pharmaceuticals (Holdings) (HKSE:06600) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

SciClone Pharmaceuticals (Holdings) 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals (Holdings)'s 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) » Definitions » 5-Year EBITDA Growth Rate

Traded in Other Exchanges

N/A

Address

381 Middle Huaihai Road, 22nd Floor, Central Plaza, Shanghai, CHN

Website

https://www.sciclone.com

SciClone Pharmaceuticals (Holdings) Ltd is a biopharmaceutical company with an integrated platform for product development and commercialization. It strategically focuses on some of the fast-growing therapeutic areas with unmet medical needs in China, primarily including oncology and severe infection. It generated revenue primarily from the sale of Zadaxin to Sinopharm.

Executives

Ubs Group Ag	2201 Interest of corporation controlled by you
Zhao Hong	2101 Beneficial owner
Gl Capital Management Gp Limited
Meng Liang	2201 Interest of corporation controlled by you
Ascendent Silver (cayman) Limited	2501 Other
Ascendent Capital Partners Ii Gp Limited	2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, Gp, L.p.	2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, L.p.	2201 Interest of corporation controlled by you
Gl Partners Capital Management Ltd.
Gl China Opportunities Carry Gp Limited
Ocean Falcon Limited	2101 Beneficial owner
Central Huijin Investment Ltd.	2201 Interest of corporation controlled by you
Bank Of China Limited	2201 Interest of corporation controlled by you
Bank Of China Group Investment Limited	2201 Interest of corporation controlled by you
Gl Capital Management Gp Ii B.c I. Ltd

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Headlines

No Headlines